Replimune

This clinical-stage biotechnology company develops a new class of oncolytic immunotherapies designed to kill tumors locally and alter the tumor microenvironment. Its pipeline includes investigational therapies being evaluated as single agents or in combination with other treatments for a range of solid tumors, including melanoma. The primary objective is to activate a systemic, tumor-specific immune response to provide durable outcomes for cancer patients.